Restoring Balance: What the FDA’s Peptide Announcement Could Mean for Patient Access and Safety

The FDA has announced a public advisory committee meeting later this summer to consider moving specific peptides to the 503A bulks list[1], which could reopen the door for licensed compounding pharmacies to prepare them.

This is a step forward for patient access and safety.

To understand why this matters, it helps to look at how we got here.

Peptides are some of the most foundational tools in modern medicine. Insulin is a peptide. So is oxytocin. So is semaglutide. At their core, peptides are short chains of amino acids that function as signaling molecules – essentially messengers that tell the body how to regulate processes like metabolism, tissue repair, immune response, and hormone activity.[2]

Because of that role, peptides have become an area of growing clinical interest across multiple therapeutic categories.

In 2023, the FDA reviewed several peptides nominated for compounding and placed many on the 503A Category 2 list.[3]  Then in 2024, the agency cited limited clinical safety data, along with concerns about immunogenicity (how the immune system might respond) and dosing variability.[4] It was a precautionary decision, and precaution is an important part of regulatory oversight.

But precaution also has downstream effects.

When these therapies were removed from the regulated compounding pathway, patient need didn’t disappear. Instead, access shifted outside of it. Patients and providers still sought these therapies, but without a legal, regulated option, a gray market began to fill the gap, one characterized by unverified sources, inconsistent quality, and little to no pharmacist oversight.[5]

In that environment, the very risks regulators aim to mitigate can become more difficult to control.

The regulated compounding system exists to prevent exactly that.

Licensed pharmacists. Quality ingredients. Inspected facilities. Established quality standards. And accountability when those standards are not met. This is the infrastructure that supports safe, customized medication when commercially available options don’t meet patient needs.[3]

With this move, that system is back in reach.

Licensed compounding pharmacies may be able to once again operate within a defined regulatory framework to prepare these peptides, bringing them back into a setting where quality, oversight, and traceability are central.[6]

Patients can access therapies within a system designed to protect them. Providers can prescribe within a framework they trust.

At Empower, this is the framework we operate in every day. As both a licensed 503A compounding pharmacy and 503B outsourcing facility, our processes are built around safety and consistency, from established sterile compounding processes to thoughtfully vetted suppliers and robust quality controls.

What this shift ultimately restores is balance.

And the idea that access and safety must be traded off against one another becomes what it should have always been: a false choice.